EVLO (Evelo Biosciences) FCF Margin %: 0.00% (As of Sep. 2023)


What is Evelo Biosciences FCF Margin %?

Evelo Biosciences EVLO -99.00% FCF Margin % is 0.00% as of Sep. 2023.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Evelo Biosciences's Free Cash Flow for the three months ended in Sep. 2023 was $-10.46 Mil. Evelo Biosciences's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Evelo Biosciences's FCF Margin % for the quarter that ended in Sep. 2023 was 0.00%.

As of today, Evelo Biosciences's current FCF Yield % is 0.00%.

The historical rank and industry rank for Evelo Biosciences's FCF Margin % or its related term are showing as below:


EVLO's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Evelo Biosciences FCF Margin % Related Terms

Evelo Biosciences FCF Margin % Historical Data

* Premium members only.

The historical data trend for Evelo Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evelo Biosciences FCF Margin % Chart

Evelo Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Evelo Biosciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

EVLO vs IMNN, EDSA, TMBR: FCF Margin % Comparison

For the Biotechnology subindustry, Evelo Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evelo Biosciences FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evelo Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Evelo Biosciences's FCF Margin % falls into.


Evelo Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Evelo Biosciences's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-101.857/0
= %

Evelo Biosciences's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-10.455/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Evelo Biosciences (EVLO) has a FCF Margin % of 0.00% as of Sep. 2023. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Evelo Biosciences and its competitors.
Is Evelo Biosciences' FCF Margin % too high?
Evelo Biosciences' current FCF Margin % is 0.00%.
How does Evelo Biosciences' FCF Margin % compare to IMNN and EDSA?
Evelo Biosciences' FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Evelo Biosciences and its competitors. Evelo Biosciences's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evelo Biosciences stock overvalued right now?
Evelo Biosciences (EVLO) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Evelo Biosciences (EVLO), the current FCF Margin % is 0.00% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evelo Biosciences Business Description

Address 620 Memorial Drive, Cambridge, MA, USA, 02139
Evelo Biosciences Inc is a clinical-stage biotechnology company focused on discovering and developing a new class of oral medicines that act on immune cells in the small intestine with systemic effects. The company is developing EDP1815 as a treatment in psoriasis and atopic dermatitis and EDP2939 in psoriasis.